Payment overview · 2025
General Payments
$2,207.00
128 reported records · 23 companies
Healthcare provider profile · identity verified
Geoffrey A Mire, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAFAYETTE, LA · NPI 1114959442
Verified facts
What the public records show
CMS Open Payments records show Geoffrey A Mire, MD received $2,207.00 in general payments during 2025 across 128 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Kerendia, Mounjaro, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyosted by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $431.58 | 19.6% | 23 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $270.57 | 12.3% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $156.96 | 7.1% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $141.20 | 6.4% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.64 | 6.3% | 9 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $124.88 | 5.7% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $116.26 | 5.3% | 4 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $97.76 | 4.4% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $93.30 | 4.2% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $93.02 | 4.2% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.11 | 4.0% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $77.49 | 3.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.15 | 3.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $70.74 | 3.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.64 | 2.8% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $39.76 | 1.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.07 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.86 | 0.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.58 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.57 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.07 | 0.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.14 | 0.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.65 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,207.00 | 128 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $215.40 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $215.26 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $190.94 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $156.96 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $156.96 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $141.20 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.64 | 9 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $124.88 | 13 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $116.26 | 4 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $97.76 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $93.30 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $93.02 | 8 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $77.49 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $74.15 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.58 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $70.74 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.20 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.20 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.64 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $55.17 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.17 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.01 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.49 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 34 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 312 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 76 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 181 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
89 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 15 |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
118 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
312 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
35 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
181 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 447 | 59 |
| Eliquis | Apixaban | 418 | 33 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 408 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 349 | 59 |
| Gabapentin | Gabapentin | 320 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 53 |
| Farxiga | Dapagliflozin Propanediol | 312 | 19 |
| Montelukast Sodium | Montelukast Sodium | 222 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 198 | 35 |
| Lisinopril | Lisinopril | 197 | 27 |
| Rexulti | Brexpiprazole | 189 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 183 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 181 | 23 |
| Furosemide | Furosemide | 178 | 36 |
| Entresto | Sacubitril/Valsartan | 177 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 42 |
| Famotidine | Famotidine | 156 | 36 |
| Xarelto | Rivaroxaban | 149 | suppressed |
| Potassium Chloride | Potassium Chloride | 148 | 24 |
| Januvia | Sitagliptin Phosphate | 139 | 11 |
| Trazodone Hcl | Trazodone Hcl | 135 | 25 |
| Metformin Hcl | Metformin Hcl | 134 | 24 |
| Carvedilol | Carvedilol | 131 | 19 |
| Sertraline Hcl | Sertraline Hcl | 127 | 22 |
| Levetiracetam | Levetiracetam | 126 | 18 |
| Gemtesa | Vibegron | 122 | suppressed |
| Alprazolam | Alprazolam | 121 | 13 |
| Vascepa | Icosapent Ethyl | 120 | suppressed |
| Myrbetriq | Mirabegron | 118 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 111 | 20 |
| Losartan Potassium | Losartan Potassium | 110 | 23 |
| Buspirone Hcl | Buspirone Hcl | 108 | 22 |
| Meloxicam | Meloxicam | 100 | 14 |
| Mirtazapine | Mirtazapine | 99 | 23 |
| Finasteride | Finasteride | 96 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 22 |
| Tramadol Hcl | Tramadol Hcl | 96 | 15 |
| Linzess | Linaclotide | 89 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 15 |
| Kerendia | Finerenone | 76 | suppressed |
| Omeprazole | Omeprazole | 76 | 11 |
| Sucralfate | Sucralfate | 73 | suppressed |
| Allopurinol | Allopurinol | 67 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 11 |
| Belsomra | Suvorexant | 63 | suppressed |
| Rivastigmine | Rivastigmine | 60 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 59 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | suppressed |
| Ezetimibe | Ezetimibe | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | 15 |
| Memantine Hcl Er | Memantine Hcl | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 15 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 51 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 14 |
| Mounjaro | Tirzepatide | 48 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 46 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Prednisone | Prednisone | 46 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Ranolazine Er | Ranolazine | 44 | suppressed |
| Simvastatin | Simvastatin | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 21 |
| Febuxostat | Febuxostat | 41 | suppressed |
| Brilinta | Ticagrelor | 39 | suppressed |
| Lidocaine | Lidocaine | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Novolin R | Insulin Regular, Human | 37 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 35 | 23 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Cefdinir | Cefdinir | 29 | 19 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Edarbi | Azilsartan Medoxomil | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 17 |
| Temazepam | Temazepam | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Digoxin | Digoxin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Prolia | Denosumab | 21 | 15 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Polymyxin B Sulfate | Polymyxin B Sulfate | 20 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Admelog | Insulin Lispro | 18 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 18 | suppressed |
| Acetazolamide | Acetazolamide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Water | Water For Irrigation,sterile | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Xyosted | Testosterone Enanthate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,207.00 · 128 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, Auvelity, Azstarys, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JATENZO, Kerendia, MOUNJARO, NEXLETOL, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XYOSTED, Xelstrym, YUPELRI, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error